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Background: The purpose of this study was to investigate the potential dose reduction to the heart, left anterior
descending (LAD) coronary artery and the ipsilateral lung for patients treated with tangential and locoregional
radiotherapy for left-sided breast cancer with enhanced inspiration gating (EIG) compared to free breathing (FB)
using the AAA algorithm. The radiobiological implication of such dose sparing was also investigated.
Methods: Thirty-two patients, who received tangential or locoregional adjuvant radiotherapy with EIG for left-sided
breast cancer, were retrospectively enrolled in this study. Each patient was CT-scanned during FB and EIG. Similar
treatment plans, with comparable target coverage, were created in the two CT-sets using the AAA algorithm. Further,
the probability of radiation induced cardiac mortality and pneumonitis were calculated using NTCP models.
Results: For tangential treatment, the median V25Gy for the heart and LAD was decreased for EIG from 2.2% to 0.2%
and 40.2% to 0.1% (p < 0.001), respectively, whereas there was no significant difference in V20Gy for the ipsilateral lung
(p = 0.109). For locoregional treatment, the median V25Gy for the heart and LAD was decreased for EIG from 3.3% to
0.2% and 51.4% to 5.1% (p < 0.001), respectively, and the median ipsilateral lung V20Gy decreased from 27.0% for FB to
21.5% (p = 0.020) for EIG. The median excess cardiac mortality probability decreased from 0.49% for FB to 0.02% for EIG
(p < 0.001) for tangential treatment and from 0.75% to 0.02% (p < 0.001) for locoregional treatment. There was
no significant difference in risk of radiation pneumonitis for tangential treatment (p = 0.179) whereas it decreased
for locoregional treatment from 6.82% for FB to 3.17% for EIG (p = 0.004).
Conclusions: In this study the AAA algorithm was used for dose calculation to the heart, LAD and left lung when
comparing the EIG and FB techniques for tangential and locoregional radiotherapy of breast cancer patients. The
results support the dose and NTCP reductions reported in previous studies where dose calculations were performed
using the pencil beam algorithm.Background
Although the use of adjuvant radiotherapy for breast
cancer reduces the risk of local and locoregional recur-
rence as well as breast cancer death [1,2], some radiation
is inevitably delivered to the heart and lungs, and for
older radiotherapy techniques, an increased risk of cardiac
mortality has been observed in radiotherapy for left-sided
breast cancer [3]. However, studies evaluating more* Correspondence: anneli.edvardsson@med.lu.se
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unless otherwise stated.modern radiotherapy techniques, have been inconclusive
regarding the increased cardiac mortality and morbidity
for left-sided breast cancer radiotherapy [3-6]. A recent
study indicated an increased risk of cardiac mortality and
morbidity with increased mean absorbed dose to the
heart, with no apparent threshold dose [7]. The left an-
terior descending (LAD) coronary artery is located in
the anterior part of the heart, and is therefore likely to
be exposed to high absorbed dose in breast radiotherapy
[8]. Higher incidence of coronary artery disease has been
seen among women irradiated for left-sided breast can-
cer, especially for LAD related disease [9]. According tontral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ern radiotherapy techniques is too short for any firm con-
clusions to be drawn and they therefore recommend that
care should continue to be taken to minimize cardiac
exposure. Until there is evidence of a threshold absorbed
dose below which there is no excess risk of cardiac
mortality and morbidity, it seems appropriate to aim at
minimizing the absorbed dose to the heart and LAD.
It has also been shown that the risk of lung complica-
tions increases with increased absorbed lung dose [3,11].
For women who developed lung cancer after breast cancer
radiotherapy, the lung cancer mortality for ipsilateral lung
cancer was higher than from contralateral lung cancer [3]
and the incidence of radiation pneumonitis has been
shown to increase with increased absorbed lung dose [11].
In a recent review [12] different cardiac sparing tech-
niques such as breathing adapted radiotherapy (BART),
prone patient positioning, intensity modulated radio-
therapy, proton beam radiotherapy and partial breast
radiotherapy were evaluated. Several studies show that
different forms of BART, such as enhanced inspiration
gating (EIG) and deep inspiration breath hold (DIBH),
can reduce the absorbed dose to the heart and lung,
while keeping the same target coverage [13-18] and as a
consequence of such dose reduction, the cardiac and
pulmonary complication probabilities can be reduced [19].
During inspiration the spatial distance between the target
volume and the heart is increased, excluding the heart and
LAD from the high-dose regions. By only irradiating dur-
ing the end-inspiration phase of the breathing cycle the
absorbed dose to the heart and LAD can be decreased. At
the same time the lung density is decreased, reducing the
relative lung volume irradiated. Hence BART provides a
possibility to reduce the cardiopulmonary dose without
compromising target coverage.
In our clinic, EIG with audio-coaching has been in clin-
ical use since 2007. All left-sided breast cancer patients,
intended to be treated with EIG, have been subjected to
both a conventional and a gated CT-scan to decide if they
benefit from EIG and consequently should be treated with
the technique.
According to Knöös et al. [20], treatment planning al-
gorithms can be divided into ‘type a’ and ‘type b’. In ‘type
b’ algorithms approximate modelling of lateral electron
transport is included, which is not accounted for in ‘type
a’ algorithms. ‘Type a’ algorithms include pencil beam
(PB) algorithms and ‘type b’ include the Collapsed Cone
(CC) and Anisotropic Analytical Algorithm (AAA). Fogliata
et al. [21] showed that PB algorithms are defective in calcu-
lations involving lung, and even more defective in calcula-
tions involving low density lung, as in the case for deep
inspiration. However, the calculation accuracy using ‘type b’
algorithms are much higher and the dose calculation
accuracy is less affected by respiratory phase. Most previoustreatment planning studies evaluating EIG and DIBH
for left-sided breast cancer have used ‘type a’ algorithms,
which do not properly account for lung heterogeneities.
To our knowledge, only few studies have used ‘type b’
algorithms [22,23].
The purpose of this treatment planning study was to
investigate the potential dose reduction to the heart, LAD
and ipsilateral lung using EIG compared to free breathing
(FB), using the AAA algorithm. The radiobiological impli-
cation of this dose difference, in the form of normal tissue
complication probability (NTCP), was also investigated.
Methods
Ethical consideration and consent
The use of the radiotherapy database for retrospective
research has been approved by the committee of the
Regional Ethical Review Board in Lund (No. 2013/742).
This research was waived informed consent.
Patient selection
Thirty-two patients, who all received adjuvant radiother-
apy for left-sided breast cancer using audio-coached EIG
[22], were randomly selected and retrospectively enrolled
in this study. The patients began their treatment between
January and December 2011. Sixteen patients received
tangential breast irradiation to the whole breast only after
lumpectomy, nine of the patients received locoregional
treatment after lumpectomy and seven patients received
locoregional treatment after mastectomy, to represent all
patients receiving radiotherapy for breast cancer. The
median age of the patients was 46 (range 40–56) years.
Respiratory gating
During EIG, the patients breathe deeper than normal,
following individually adjustable inhale (3.6 to 5.2 s in this
study) and exhale times (3.6 to 5.3 s in this study). Unlike
for DIBH, where longer breath holds are used, the pa-
tients do not perform normal breathing between the deep
breaths. The real-time positioning management system
(RPM™, Varian Medical Systems, Palo Alto, CA) was used
to monitor the patients’ breathing. This system consists of
a marker block, with six reflective markers, placed on the
chest of the patient, and infrared light reflected by these
markers is detected by a camera to monitor the antero-
posterior movement of the box. The marker block was
positioned on the sternum, slightly to the right to avoid ir-
radiating through the box. The image acquisition and ir-
radiation was automatically turned on in a preselected
interval of the breathing cycle, referred to as the gating
window. Gating in the end-inspiration phase of enhanced
free breathing based on the respiration amplitude was
used. The patients were audio-coached during a training
session (approximately 30 minutes), CT-scanning, set-up
imaging and the radiotherapy treatment.
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Both EIG and FB CT scans were acquired for all 32 pa-
tients. For 27 patients a 2-slice GE HiSpeed Nx/i Pro (GE
Healthcare, Madison, WI) was used and for five patients a
64-slice Siemens Somatom definition AS plus (Siemens
Medical Solutions, Erlangen, Germany) was used. The
slice thickness was 3 mm and the acquisition was made in
axial scan mode for EIG and helical scan mode for FB.
The patients were positioned in a standard breast board
(Posiboard-2, Civco Medical Solution, IA, USA) with both
arms above the head. The CT scanning was automatically
started when the breathing curve entered the gating
window.
Delineation of structures
Structures were delineated in both the EIG and FB CT-
sets by two radiation oncologists. The two oncologists
delineated all structures however they divided the work
so that a specific structure in all CT sets was delineated
by the same oncologist. For tangential breast irradiation
to the whole breast only after lumpectomy, the PTV was
defined as the clinical limits of the breast, with a minimum
of 10 mm margin to all glandular tissue. The CTV-T was
defined as the volume where the tumor had been located,
approximately equivalent to a quadrant of the breast. For
locoregional treatment after lumpectomy, the PTV was de-
fined as the clinical limits of the breast, ipsilateral axillary
lymph nodes level I-III, and supra- and infraclavicular
fossa. The CTV-T was defined as above. For locoregional
treatment after mastectomy, the PTV was defined as the
part of the thoracic wall were the breast had been located
(visualized on CT scans by markers), ipsilateral axillary
lymph nodes level I-III, and supra- and infraclavicular
fossa. No CTV-T was delineated for these patients. The
PTV was cropped 5 mm from the skin surface. The organs
at risk (OAR) delineated were the heart, LAD and ipsilat-
eral lung. The heart and LAD were manually delineated
whereas the ipsilateral lung was automatically delineated
using the segmentation wizard in the treatment planning
system (TPS, Eclipse, version 10.0, Varian Medical Systems,
Palo Alto, CA) and then manually verified. The heart was
defined as the entire myocardium, excluding the peri-
cardium where a distinction could be made, starting su-
periorly at the beginning of pulmonary trunc and aorta.
LAD was delineated starting from the exit of left coron-
ary artery (which was thus included) from aorta, continu-
ing in the anterior interventricular sulcus down to as close
to the apex as the sulcus could be visualized. All OARs
were delineated without margins.
Treatment planning
The treatment planning was carried out by one physicist,
on the basis of the guidelines provided by the Swedish
breast cancer group [24]. According to these nationalguidelines, dose coverage of the PTV should be priori-
tized higher than the OARs for lobular and multifocal
breast cancer. Otherwise the constraints and guideline
values for the heart and lung dose should be prioritized
higher than dose coverage of the PTV. Dose coverage of
the CTV-T should always be first priority. In this study,
dose coverage of the PTV was always prioritized over
the absorbed dose to the OARs regardless of the patients’
diagnosis. The main goals of the treatment plans were that
100% of the CTV-T volume should be covered by 95% of
the prescribed dose (V95%,CTV-T =100%), 100% of the PTV
volume should be covered by 93% of the prescribed dose
(V93%,PTV =100%) and the volume receiving more than
105% of the prescribed dose (V105%) should be minimized.
At the same time the absorbed dose to the OARs was kept
as low as possible. Although the national guidelines were
not completely followed, this way of performing the treat-
ment planning gave the opportunity to evaluate the pos-
sible decrease in doses to risk organs, if the dose coverage
of the PTV was prioritized higher than the OAR con-
straints. Regarding the arrangement of the treatment
beams, essentially identical plans were created in both the
EIG and FB CT-images. Only minor differences in the
placement of the additional fields, gantry angle and field
weight were allowed to get comparable target coverage
between the two plans. The absorbed dose was normal-
ized to the PTV mean dose and the calculation algo-
rithm used was the AAA version 10.0.28. The prescribed
dose was 50 Gy in 25 fractions. Three-dimensional con-
formal treatment planning using a single isocenter tech-
nique was used.
For tangential treatment planning, two tangential 6 MV
photon fields with a posterior PTV margin of 5 mm were
used. For dose homogenization, 10 or 18 MV fields, with
the same shape as the 6 MV fields, were added for some
of the patients. For the same reason, additional smaller
fields, with lower field weight, were also added for all
of the patients. All fields were conformed using the
Millenium multileaf collimator (Varian Medical Systems,
Palo Alto, CA) with a central and peripheral leaf width of
5 and 10 mm, respectively.
For locoregional treatment planning, the PTV was di-
vided into a cranial and caudal part with the isocenter
placed in the junction. The treatment planning of the
caudal part was carried out in the same way as for tan-
gential treatment, with at least one additional field, with
lower field weight, covering the junction. For the cra-
nial part, anterior and posterior photon fields were
used. For the anterior field the energy used depended
on the location of the target. Also a mixture of different
energies was used. For the posterior field, the highest
energy was always used (10 or 18 MV). A posterior
field with lower field weight, shielding for the lung, was
also added.
Figure 1 Definition of the maximum heart distance. The
maximum heart distance (MHD) is defined as the maximal distance
between the contour of the heart and the posterior MLC of a
tangential field.
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The probability for cardiac mortality and radiation pneu-








P Dið Þ ¼ 2−exp eγ 1−Di=D50ð Þf g ð2Þ
where Di is the absorbed dose in each dose bin, i, of
the differential dose volume histogram (DVH), D50 is the
dose resulting in 50% complication probability, γ is the
maximum relative slope of the dose–response curve, n is
the number of DVH dose bins, ΔVi = Vi/V where Vi is
the volume of the each dose bin and V is the total vol-
ume of the organ. The relative seriality factor, s (range 0
to 1), describes the tissue architecture. Input data for the
NTCP calculations with endpoint excess cardiac mortal-
ity was taken from Gagliardi et. al. [26] for the entire
heart volume: s = 1, γ = 1.28 and D50 = 52.3 Gy. For the
endpoint radiation pneumonitis input data was taken
from Gagliardi et al. [11], corrected for the use of the
AAA algorithm by the use of algorithm-specific NTCP
parameters determined by Hedin et al. [27]: s = 0.012,
γ = 0.974 and D50 = 27.52 Gy for tangential treatment
and s = 0.012, γ = 0.966 and D50 = 29.23 Gy for locore-
gional treatment.
Data analysis
DVHs, with a dose bin size of 0.05 Gy, were retrieved
from the TPS. For the heart and LAD, the mean absorbed
dose (Dmean,heart/LAD), the near maximum absorbed dose
(the dose to 2% of the volume, D2%,heart/LAD) and the
volume receiving more than 25 Gy (V25Gy,heart/LAD) were
compared between EIG and FB. For the ipsilateral lung
the mean absorbed dose (Dmean,lung) and the volume re-
ceiving more than 20 Gy (V20Gy,lung) were compared. Also
the CTV-T volume covered by 95% of the prescribed dose
(V95%,CTV-T) and the PTV volume covered by 93% of the
prescribed dose (V93%,PTV) were compared. Additionally,
the structure volumes (VPTV/CTV-T/heart/LAD/lung) were re-
trieved from the TPS and the maximum heart distance
(MHD) was measured in the beam’s eye view. The MHD
is the maximal distance between the contour of the heart
and the posterior MLC of a tangential field (Figure 1). The
breathing amplitudes during the CT session were retrieved
from the RPM system.
Two-sided paired Wilcoxon tests were carried out to
evaluate the difference between the two treatment tech-
niques. Two-sided unpaired Wilcoxon tests were carried
out to evaluate the difference between the tangential and
locoregional groups of patients. Values of p < 0.01 were
considered statistically significant.Results
For both tangential and locoregional treatment, the
Dmean,heart, Dmean,LAD, D2%,heart, D2%,LAD, V25Gy,heart and
V25Gy,LAD were significantly decreased for EIG compared
to FB (p < 0.001) (Table 1, Figure 2). Also the MHD was
significantly decreased for both tangential and locoregio-
nal treatment (p < 0.001). Based on NTCP calculations,
the excess cardiac mortality probability was significantly
decreased (p < 0.001) for EIG compared to FB for both
tangential and locoregional treatment (Table 2).
For tangential treatment, there was no significant dif-
ference in Dmean,lung and V20Gy,lung between EIG and FB
(p = 0.215 and p = 0.109, respectively) (Table 1, Figure 2).
Further, there was no significant difference (p = 0.179)
in the risk of clinical pneumonitis between EIG and FB
(Table 2). For locoregional treatment, however, there
was a statistically significant decrease in Dmean,lung for
the ipsilateral lung for EIG compared to FB (p = 0.002)
(Table 1, Figure 2) whereas there was no significant
difference in V20Gy,lung (p = 0.020). The risk of clinical
pneumonitis was significantly decreased (p = 0.004) for
EIG compared to FB for locoregional treatment (Table 2).
The median breathing amplitude for EIG during
the CT session was 7.0 (5.1-14.4) mm for tangential
treatment and 6.9 (4.9-11.4) mm for locoregional
Table 1 Treatment planning data for target and organs at risk for free breathing (FB) and enhanced inspiation gating
(EIG) for tangential and locoregional treatment, presented as median values, range in brackets and p-values for paired
Wilcoxon tests
Tangential treatment Locoregional treatment
FB EIG p FB EIG p
VPTV (cm
3) 891 [290-2622] 888 [297-2557] 0.469 1136 [325-2670] 1092 [308-2656] 0.278
V93%,PTV (%) 98.7 [96.9-99.2] 98.2 [96.8-99.4] 0.017 98.2 [96.4-99.3] 98.3 [96.4-99.3] 0.255
VCTV-T (cm
3) 40 [16-215] 43 [17-217] <0.001 40 [6-93] 41 [6-93] 0.492
V95%,CTV-T (%) 100.0 [98.0-100.0] 100.0 [98.9-100.0] 0.019 99.9 [95.8-100.0] 99.9 [95.7-100.0] 0.469
Vheart (cm
3) 593 [387-771] 580 [399-747] 0.438 613 [447-783] 615 [455-743] 0.255
Dmean,heart (Gy) 2.5 [1.3-4.4] 1.3 [0.8-2.1] <0.001 3.1 [1.9-5.4] 1.5 [1.0-3.8] <0.001
D2%,heart (Gy) 28.5 [6.1-44.2] 5.2 [3.2-21.0] <0.001 38.4 [9.6-46.1] 5.5 [3.8-41.7] <0.001
V25Gy,heart (%) 2.2 [0.3-6.3] 0.2 [0.0-1.7] <0.001 3.3 [0.9-7.6] 0.2 [0.0-4.1] <0.001
MHD* (cm) 1.3 [0.5-2.4] 0.4 [0.0-1.8] <0.001 1.7 [0.9-2.9] 0.6 [0.0-1.9] <0.001
VLAD (cm
3) 1.8 [1.1-2.8] 1.8 [1.0-3.0] 0.313 1.7 [1.0-3.3] 1.8 [0.7-3.1] 0.234
Dmean,LAD (Gy) 18.5 [3.5-39.8] 5.5 [2.4-9.3] <0.001 25.4 [8.7-33.1] 8.0 [4.1-30.6] <0.001
D2%,LAD (Gy) 44.7 [8.6-48.8] 16.7 [3.7-34.6] <0.001 46.1 [27.8-48.9] 28.9 [6.5-46.9] 0.002
V25Gy,LAD (%) 40.2 [0.0-87.7] 0.1 [0.0-7.2] <0.001 51.4 [3.5-75.8] 5.1 [0.0-62.4] <0.001
Vlung (cm
3) 1132 [786-1617] 1765 [1224-2325] <0.001 1047 [626-1249] 1683 [1080-2410] <0.001
Dmean,lung (Gy) 5.4 [2.1-9.4] 5.5 [2.6-9.1] 0.215 14.0 [6.4-18.9] 11.2 [6.1-16.4] 0.002
V20Gy,lung (%) 9.1 [2.2-17.2] 9.1 [2.9-17.2] 0.109 27.0 [8.7-38.8] 21.5 [7.9-31.9] 0.020
*Maximum heart distance.
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tudes during EIG were comparable for the tangential
and locoregional groups of patients. Comparisons
of the structure volumes and target coverage are
presented in Table 1.
Discussion
Several previous studies have emphasized the limitations
of ‘type a’ dose calculation algorithms in treatment situ-
ations including lung tissue. In general, due to the fact
that lateral electron transport is not scaled appropriately,Figure 2 Mean dose volume histograms. Mean dose volume histogram
comparing EIG (solid lines) and FB (dashed lines) for LAD (black), heart (red‘type a’ algorithms will overestimate the coverage of the
target volumes and underestimate the low dose volumes
in nearby risk organs. Since the effect is smaller in the
50% dose region, the dose to risk organs has previously
often been reported in terms of V50% [14]. The range
effect is expected to be larger if the lung density is lower,
and it has been concluded that these types of algorithms
are not suitable for comparing treatment techniques where
the lung density varies, such as during BART for breast
cancer [13,14,18,19]. The AAA algorithm, which is used in
this study, is known to give more accurate calculations for tangential treatment (left) and locoregional treatment (right)
), ipsilateral lung (green) and PTV (blue).
Table 2 Excess cardiac mortality probability and risk of radiation pneumonitis in percent for tangential and
locoregional treatment, presented as median values, range in brackets and p-values for paired Wilcoxon tests
Tangential treatment Locoregional treatment
FB EIG p FB EIG p
Excess cardiac mortality probability 0.49 [0.03-1.74] 0.02 [0.00-0.37] <0.001 0.75 [0.12-2.14] 0.02 [0.00-1.01] <0.001
Risk of radiation pneumonitis 0.31 [0.04-1.99] 0.38 [0.05-1.78] 0.179 6.82 [0.47-17.72] 3.17 [0.41-11.51] 0.004
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pared to the PB algorithm [21]. Especially, the accuracy is
increased in the low-dose and the high-dose regions. This
is important for NTCP calculations, which requires in-
formation of the entire DVH. In this study, we have re-
placed the previously used NTCP parameters, which were
derived using a PB algorithm according to the studies by
Gagliardi et al. [11,26], by algorithm-specific parameters
for the endpoint radiation pneumonitis, as determined by
Hedin et al. [27]. Good calculation accuracy in the high-
dose region is also important for estimating the effects on
the LAD, for which an increased incidence of coronary
artery stenosis have been associated with high doses [9].
Radiotherapy for breast cancer is an adjuvant therapy,
used to reduce the recurrence rate and increase survival.
According to Darby et al. and Clarke et al. [1,2], one re-
currence is avoided for approximately every fifth patient
irradiated for breast cancer and one breast cancer death
is avoided for approximately every twentieth patient irra-
diated. Consequently, due to the lack of predictive methods
the majority of the breast cancer patients will not benefit
from the radiotherapy treatment. Additionally, this is also a
large group of patients with an expected long-time survival,
which emphasizes the importance to keep the long-time
side effects as low as possible. The results from this study
show that EIG significantly reduce the heart and LAD
absorbed doses and the excess cardiac mortality probability
for both tangential and locoregional treatment and the ipsi-
lateral lung absorbed dose and risk of clinical pneumonitis
for locoregional treatment. These results support previ-
ously published studies using PB algorithms showing that
EIG reduces doses to risk organs and NTCP [14,19].
Comparing tangential and locoregional treatment, the
potential to reduce the absorbed dose to the heart and
LAD is higher using EIG for locoregional treatment. The
absolute reduction in the median excess cardiac mortality
probability was 0.73 percentage points for locoregional
treatment and 0.47 percentage points for tangential treat-
ment, implying a larger absolute sparing in excess cardiac
mortality probability using EIG for locoregional treatment
than for tangential treatment. Also, the absorbed dose to
the ipsilateral lung and excess risk of radiation pneumon-
itis were significantly decreased for locoregional treat-
ment, but not seen for tangential treatment. The internal
mammary nodes (IMN) were not included in the target in
this study, following clinical practice. Inclusion of theIMNs in the target implies higher doses to the heart and
ipsilateral lung, and hence potentially larger dose reduction
to OARs using BART. In the studies by Korreman et al.
[14,19] and Hjelstuen et al. [18] the IMNs were included in
the target and the absorbed doses to the heart, LAD and
ipsilateral lung were higher compared to this study.
This study confirms, using the AAA algorithm, that
EIG can reduce the absorbed dose to the heart and LAD
and the cardiac mortality probability shown in previous
studies using PB algorithms [14,19]. Furthermore, this
study shows that this is also the case although IMNs are
excluded in the target. Also the absorbed dose to the ip-
silateral lung was decreased for locoregional treatment
but not for tangential treatment. Available studies report
conflicting results regarding the absorbed dose for the
ipsilateral lung for tangential treatment using BART
[13,15-17]. A possible reason for this could be that larger
breathing amplitudes (18 mm in [13] and 10.9 mm for
EIG and 21.3 mm for DIBH in [17]) were used in these
studies which resulted in a decreased lung dose com-
pared to the present study. Damkjær et al. [22] showed
that a smaller lung volume was irradiated to high absorbed
dose using DIBH compared to EIG due to a larger breath-
ing amplitude for this treatment technique. Hence, in-
creased breathing amplitudes could possibly result in
decreased ipsilateral lung dose and NTCP also for tan-
gential treatment. Larger breathing amplitudes are also
required to completely remove the heart from the treat-
ment fields, especially for locoregional treatment due to
the higher MHD for this group (Table 1). For 6 out of
the 16 patients receiving tangential treatment and 4 out
of the 16 patients receiving locoregional treatment, the
heart was completely outside the treatment fields for
EIG. However, the volume receiving high absorbed dose
(V25Gy) was reduced for all except one of the patients.
For none of the patients the heart was completely out-
side the treatment fields for FB. Since the heart can
be considered to be a serial organ for the endpoint car-
diac mortality [26], possibly due to irradiation of the
coronary arteries, a reduction of the maximum dose to
the heart and coronary arteries is of great importance.
There were no significant differences in V93%,PTV or
V95%,CTV-T for neither tangential nor locoregional treat-
ment. The volume of CTV-T was significantly larger for
EIG compared to FB for tangential treatment. The reason
for this is not known. The difference was rather small and
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Except for the expected increase of the ipsilateral lung
volume, there were no other significant differences in
the structure volumes. Hence the structure volumes and
treatment plans can be considered comparable between
FB and EIG. Comparable target coverage is crucial to be
able to compare the absorbed dose to the OARs.
The challenges in defining the heart volume and the
subregions of the heart have been pointed out by the
QUANTEC group [28]. Lorenzen et al. [29] showed a
large uncertainty in the estimated absorbed dose to es-
pecially LAD but also to the heart due to inter-observer
variations in the delineation of these structures. No con-
trast was used for visualization of LAD in this study and
therefore the whole LAD was not distinguishable in the
CT images, leading to uncertainties in the delineation of
LAD. However, LAD was similarly delineated by the same
oncologist in the EIG and FB CT sets and the uncertainty
in LAD delineation is only believed to have minor impact
on the comparison of these two techniques. However, this
might affect the comparison of the results in this study
with other studies.
The parameters used to calculate the cardiac mortality
probability was determined assuming a homogeneous ra-
diation sensitivity within the heart. The dose reduction
observed with EIG occurs primarily in the anterior part
of the heart where LAD is positioned and therefore a
greater reduction of long-term ischemic disease might be
expected. The parameters used to calculate the cardiac
mortality probability in this study are based on older radio-
therapy techniques and may not reflect the radiotherapy
techniques of today. Also, the NTCP parameters are based
on data with higher incidence of excess cardiac mortality
than calculated in the present study. Hence the magnitude
of the heart NTCP should not be interpreted as exact,
however for the purpose of this study, to compare two dif-
ferent treatment techniques it gives a reasonable estimate
of the complication probability for the two techniques.
According to the QUANTEC group [30] approximately
1–5% of the patients irradiated for breast cancer develop
clinically significant symptomatic radiation pneumonitis.
The NTCP calculations of the risk of radiation pneumon-
itis presented in this study (Table 2), using the parameters
by Gagliardi et al. [11] corrected for the use of the AAA
algorithm by the use of algorithm-specific NTCP parame-
ters determined by Hedin et al. [27], are in close agree-
ment with the risk of developing radiation pneumonitis
according to the QUANTEC group.
According to the guidelines by the Swedish breast can-
cer group [24], sparing of the heart should be prioritized
over the target coverage for all but lobular and multifocal
breast cancer, which means that target coverage is com-
promised against sparing of the OARs. However, due to
the increased distance between the breast and the heartduring EIG, the target coverage does not have to be com-
promised. Consequently, the gain from EIG could be re-
duced OAR absorbed doses or increased target coverage
with the same OAR doses or a combination of the two. In
this study, the target was always prioritized over the OARs
and hence this study demonstrates the OAR dose-sparing
possibility using EIG.
Until the risk of cardiac mortality and morbidity from
modern radiotherapy techniques for breast cancer is
better known it seems reasonable that the absorbed
dose to the heart should be kept as low as possible. The
QUANTEC group [28] recommends that for patients with
breast cancer the irradiated heart volume should be mini-
mized as much as possible without compromising target
coverage. This is shown to be possible for EIG using the
AAA algorithm in this study, confirming the dose sparing
of risk organs shown in previously published research
using PB algorithms.
Conclusions
Using the AAA algorithm for dose calculation, enhanced
inspiration gating significantly decreases the absorbed dose
to the heart and left anterior descending coronary artery
without compromising the target coverage, for both tan-
gential and locoregional treatment, resulting in decreased
cardiac mortality probability. The absorbed dose to the ip-
silateral lung was significantly decreased for locoregional
treatment, resulting in decreased radiation pneumonitis
probability for this patient group. The results support the
dose and NTCP reductions reported in previous studies
where dose calculations were performed using the pencil
beam algorithm.
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